Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gilead Sciences, Inc.
  6. Financials
    GILD   US3755581036

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 82 20973 03191 08178 683--
Enterprise Value (EV)1 82 450103 910118 53095 01092 25588 257
P/E ratio 15,4x583x14,7x17,8x13,3x12,6x
Yield 3,88%4,67%3,91%4,63%4,82%5,06%
Capitalization / Revenue 3,66x2,96x3,34x3,21x3,24x3,14x
EV / Revenue 3,67x4,21x4,34x3,87x3,80x3,53x
EV / EBITDA 6,61x7,88x8,12x7,34x7,53x7,00x
Price to Book 3,65x4,04x4,32x3,54x3,18x2,83x
Nbr of stocks (in thousands) 1 265 1461 253 5281 254 3841 254 313--
Reference price (USD) 65,058,372,662,762,762,7
Announcement Date 02/04/202002/04/202102/01/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 22 44924 68927 30524 54324 29925 028
EBITDA1 12 46813 18414 59812 94912 25212 616
Operating profit (EBIT)1 11 06411 70412 54811 20010 68311 197
Operating Margin 49,3%47,4%46,0%45,6%44,0%44,7%
Pre-Tax Profit (EBT)1 5 1601 6698 2785 1257 5597 586
Net income1 5 3861236 2254 2275 9296 181
Net margin 24,0%0,50%22,8%17,2%24,4%24,7%
EPS2 4,220,104,933,534,714,98
Dividend per Share2 2,522,722,842,903,023,17
Announcement Date 02/04/202002/04/202102/01/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 7 4217 2446 5905 8525 9176 260
EBITDA1 4 9022 0424 0493 1073 1362 712
Operating profit (EBIT)1 4 3791 5073 5242 6152 6422 442
Operating Margin 59,0%20,8%53,5%44,7%44,6%39,0%
Pre-Tax Profit (EBT)1 3 438759-1521 6721 7541 785
Net income1 2 59238219,01 3591 4341 376
Net margin 34,9%5,27%0,29%23,2%24,2%22,0%
EPS2 2,050,300,021,091,131,10
Dividend per Share ------
Announcement Date 10/28/202102/01/202204/28/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 24130 87927 44916 32713 5729 574
Net Cash position1 ------
Leverage (Debt / EBITDA) 0,02x2,34x1,88x1,26x1,11x0,76x
Free Cash Flow1 8 3197 51810 8059 3828 8178 860
ROE (Net Profit / Equities) 38,3%43,8%46,8%37,2%29,1%26,9%
Shareholders' equity1 14 05528113 30511 37920 34522 949
ROA (Net Profit / Asset) 8,60%0,19%9,13%9,06%7,83%8,05%
Assets1 62 65165 07968 18046 66475 74276 836
Book Value Per Share2 17,814,416,817,719,722,2
Cash Flow per Share2 7,166,479,027,796,586,47
Capex1 825650579662668682
Capex / Sales 3,67%2,63%2,12%2,70%2,75%2,72%
Announcement Date 02/04/202002/04/202102/01/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
GSK to buy Sierra Oncology amid pressure to boost drug pipeline
Key data
Capitalization (USD) 78 683 082 593
Net sales (USD) 27 305 000 000
Number of employees 14 400
Sales / Employee (USD) 1 896 181
Free-Float 99,9%
Free-Float capitalization (USD) 78 639 328 481
Avg. Exchange 20 sessions (USD) 478 660 644
Average Daily Capital Traded 0,61%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA